Journal article
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286
The Journal of infectious diseases, v 211(5), pp 780-790
01 Mar 2015
PMCID: PMC4334803
PMID: 25214516
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Rifaximin, a nonabsorbable antibiotic that decreases lipopolysaccharide (LPS) in cirrhotics, may decrease the elevated levels of microbial translocation, T-cell activation and inflammation in human immunodeficiency virus (HIV)-positive immune nonresponders to antiretroviral therapy (ART).
HIV-positive adults receiving ART for ≥96 weeks with undetectable viremia for ≥48 weeks and CD4(+) T-cell counts <350 cells/mm(3) were randomized 2:1 to rifaximin versus no study treatment for 4 weeks. T-cell activation, LPS, and soluble CD14 were measured at baseline and at weeks 2, 4, and 8. Wilcoxon rank sum tests compared changes between arms.
Compared with no study treatment (n = 22), rifaximin (n = 43) use was associated with a significant difference between study arms in the change from baseline to week 4 for CD8(+)T-cell activation (median change, 0.0% with rifaximin vs +0.6% with no treatment; P = .03). This difference was driven by an increase in the no-study-treatment arm because there was no significant change within the rifaximin arm. Similarly, although there were significant differences between study arms in change from baseline to week 2 for LPS and soluble CD14, there were no significant changes within the rifaximin arm.
In immune nonresponders to ART, rifaximin minimally affected microbial translocation and CD8(+)T-cell activation. Trial registration number. NCT01466595.
Metrics
Details
- Title
- Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286
- Creators
- Allan R Tenorio - Department of MedicineEllen S Chan - Harvard UniversityRonald J Bosch - Harvard UniversityBernard J C Macatangay - University of PittsburghSarah W Read - National Institutes of HealthSuria Yesmin - Social and Scientific SystemsBabafemi Taiwo - Northwestern UniversityDavid M Margolis - University of North Carolina at Chapel HillJeffrey M Jacobson - Drexel UniversityAlan L Landay - Rush UniversityCara C Wilson - University of DenverA5286 Team
- Publication Details
- The Journal of infectious diseases, v 211(5), pp 780-790
- Publisher
- Oxford University Press
- Grant note
- UM1 AI069447 / NIAID NIH HHS U01 AI069534 / NIAID NIH HHS AI069470 / NIAID NIH HHS UM1 AI069556 / NIAID NIH HHS U01 AI069452 / NIAID NIH HHS AI069419 / NIAID NIH HHS AI069432 / NIAID NIH HHS U01 AI069471 / NIAID NIH HHS AI069481 / NIAID NIH HHS UM1 AI069471 / NIAID NIH HHS UM1 AI069503 / NIAID NIH HHS AI069424 / NIAID NIH HHS AI069503 / NIAID NIH HHS AI069477 / NIAID NIH HHS TR001070 / NCATS NIH HHS UM1 AI069534 / NIAID NIH HHS U01 AI069447 / NIAID NIH HHS U01 AI069556 / NIAID NIH HHS AI50410 / NIAID NIH HHS U01 AI069494 / NIAID NIH HHS UM1 AI069452 / NIAID NIH HHS U01 AI069439 / NIAID NIH HHS UM1 AI069439 / NIAID NIH HHS AI069447 / NIAID NIH HHS AI069532 / NIAID NIH HHS UM1 AI069494 / NIAID NIH HHS U01 AI069432 / NIAID NIH HHS AI069415 / NIAID NIH HHS AI073961 / NIAID NIH HHS U01 AI068636 / NIAID NIH HHS UL1 TR000457 / NCATS NIH HHS AI069412 / NIAID NIH HHS UL1 TR001111 / NCATS NIH HHS P30 AI045008 / NIAID NIH HHS U01 AI069511 / NIAID NIH HHS P30 AI050410 / NIAID NIH HHS A1025439 / PHS HHS U01 AI069477 / NIAID NIH HHS AL050404 / PHS HHS U01 AI069501 / NIAID NIH HHS RR024160 / NCRR NIH HHS UM1 AI069424 / NIAID NIH HHS TR001111 / NCATS NIH HHS UM1 AI068634 / NIAID NIH HHS U01 AI069419 / NIAID NIH HHS AI069501 / NIAID NIH HHS U01 AI069502 / NIAID NIH HHS UM1 AI069532 / NIAID NIH HHS U01 AI069412 / NIAID NIH HHS AI069494 / NIAID NIH HHS UM1 AI069423 / NIAID NIH HHS UM1 AI069415 / NIAID NIH HHS UL1 RR024160 / NCRR NIH HHS U01 AI069423 / NIAID NIH HHS U01 AI069532 / NIAID NIH HHS AI068636 / NIAID NIH HHS UM1 AI068636 / NIAID NIH HHS U01 AI069481 / NIAID NIH HHS P30 AI073961 / NIAID NIH HHS UL1 TR001070 / NCATS NIH HHS UM1 AI069418 / NIAID NIH HHS U01 AI069415 / NIAID NIH HHS AI069418 / NIAID NIH HHS UM1 AI069502 / NIAID NIH HHS U01 AI069470 / NIAID NIH HHS UM1 AI069412 / NIAID NIH HHS UM1 AI069481 / NIAID NIH HHS AI069471 / NIAID NIH HHS UM1 AI106701 / NIAID NIH HHS UM1 AI069501 / NIAID NIH HHS AI069511-08 / NIAID NIH HHS AI069423 / NIAID NIH HHS UM1 AI069470 / NIAID NIH HHS AI069556 / NIAID NIH HHS AI069502 / NIAID NIH HHS AI069452 / NIAID NIH HHS U01 AI069503 / NIAID NIH HHS U01 AI069418 / NIAID NIH HHS AI069439 / NIAID NIH HHS UL1 TR000042 / NCATS NIH HHS UL1 TR001082 / NCATS NIH HHS UM1 AI069511 / NIAID NIH HHS UM1 AI069477 / NIAID NIH HHS UL1 TR000439 / NCATS NIH HHS AI045008 / NIAID NIH HHS AI069534 / NIAID NIH HHS TR000439 / NCATS NIH HHS UM1 AI069432 / NIAID NIH HHS TR001082 / NCATS NIH HHS U01 AI069424 / NIAID NIH HHS UM1 AI069419 / NIAID NIH HHS U01 AI068634 / NIAID NIH HHS
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000350222000013
- Scopus ID
- 2-s2.0-84939509426
- Other Identifier
- 991019335327604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases
- Microbiology